The amyotrophic lateral sclerosis (ALS) treatment market comprises drugs that provide symptomatic relief and help slow down progression of the neurodegenerative disease. Drugs approved for ALS treatment work by various mechanisms such as inhibiting glutamate-mediated neuronal death, regulating calcium homeostasis, and reducing neuro-inflammation. The need for effective therapies is rising due to the increasing prevalence of ALS globally.

The Global amyotrophic lateral sclerosis (ALS) treatment market is estimated to be valued at US$ 692.77 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the amyotrophic lateral sclerosis (ALS) treatment are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi ,Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, ADVANZ PHARMA. The key players are focused on developing new drug candidates and therapies to expand their product portfolios.

The global ALS treatment market provides numerous growth opportunities due to rising research funding to develop novel drugs and the availability of late-stage pipeline drugs. Further, collaborations between academic research institutes and pharma companies will help accelerate drug development programs.

Geographically, North America dominates the global ALS treatment market and is expected to continue its dominance form 2023 to 2030. However, Asia Pacific is anticipated to exhibit the fastest growth owing to improving healthcare infrastructure and increasing per capita income.

Market drivers

The major driver for the ALS treatment market is the increasing prevalence of ALS globally. As per estimates, over 16,000 Americans are currently living with ALS. Other key drivers include rising research funding from public-private organizations to develop new drugs, promising late-stage pipeline drugs, and growing awareness about the disease treatment options. Further, the lack of curative options and need for medications that can effectively slow disease progression are also propelling the market growth.

PEST Analysis

Political: Government regulations play a big role in this market. Regulatory bodies approve new drugs and provide funding for research. Favourable regulations accelerate drug development and patient access.

Economic: As ALS is a rare disease, cost of treatment is very high. The economic environment impacts healthcare spending and funding for research. A recession can reduce available funding.

Social: Awareness programs help improve diagnosis rates by educating people about symptoms. Social media support groups provide a platform for patients to share experiences and boost community support.

Technological: Advancements in genetic research and biomarkers help identify targets for new therapies. Stem cell therapy and gene therapy are promising areas of research. Developing non-invasive diagnostic tools through digital technologies can improve early detection.

Market concentration

North America dominates the market with the highest value share due to presence of major players, high healthcare spending, and supportive patient access programs for orphan drugs. Europe is the second largest market due to increasing research funding from government bodies in countries like UK, Germany, and France.

Fastest growing region

Asia Pacific is poised to grow at the fastest rate due to rising healthcare expenditure, growing patients base with increasing disease prevalence, and improving access to diagnosis and treatment. Initiatives to build healthcare infrastructure in countries like China and India will support market growth in the coming years through local manufacturing and investments from global players exploring emerging markets.